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Abstract
Background: Many patients with advanced cancer receive chemotherapy close to death and are referred too late to palliative
or hospice care, and therefore die under therapy or in intensive care units. Oncologists still have difficulties in involving patients
appropriately in decisions about limiting tumor-specific or life-prolonging treatment.
Objective: The aim of this Ethics Policy for Advanced Care Planning and Limiting Treatment Study is to develop an ethical
guideline for end-of-life decisions and to evaluate the impact of this guideline on clinical practice regarding the following target
goals: reduction of decisional conflicts, improvement of documentation transparency and traceability, reduction of distress of the
caregiver team, and better knowledge and consideration of patients’ preferences.
Methods: This is a protocol for a pre-post interventional study that analyzes the clinical practice on treatment limitation before
and after the guideline implementation. An embedded researcher design with a mixed-method approach encompassing both
qualitative and quantitative methods is used. The study consists of three stages: (1) the preinterventional phase, (2) the intervention
(development and implementation of the guideline), and 3) the postinterventional phase (evaluation of the guideline’s impact on
clinical practice). We evaluate the process of decision-making related to limiting treatment from different perspectives of
oncologists, nurses, and patients; comparing them to each other will allow us to develop the guideline based on the interests of
all parties.
Results: The first preintervention data of the project have already been published, which detailed a qualitative study with
oncologists and oncology nurses (n=29), where different approaches to initiation of end-of-life discussions were ethically weighted.
A framework for oncologists was elaborated, and the study favored an anticipatory approach of preparing patients for forgoing
therapy throughout the course of disease. Another preimplementational study of current decision-making practice (n=567 patients
documented) demonstrated that decisions to limit treatment preceded the death of many cancer patients (62/76, 82% of deceased
patients). However, such decisions were usually made in the last week of life, which was relatively late.
Conclusions: The intervention will be evaluated with respect to the following endpoints: better knowledge and consideration
of patients’ treatment wishes; reduction of decisional conflicts; improvement of documentation transparency and traceability;
and reduction of the psychological and moral distress of a caregiver team.
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Introduction
Decision-making to limit a tumor-specific and life-prolonging
treatment in patients with advanced cancer is one of the most
difficult tasks in end-of-life care and is often accompanied by
psychological and ethical challenges. Many patients with
advanced cancer receive aggressive chemotherapy close to death
and are referred to palliative or hospice care too late, and die
under therapy or in the intensive care unit [1-3]. Thus, the
number of patients receiving chemotherapy between two weeks
and death has been constantly rising [4]. The literature suggests
that discussions about patients’ end-of-life preferences and
treatment limitation should occur much earlier. Such discussions
have been associated with better patient outcomes in terms of
increasing patients’ quality of life and reducing patients’ anxiety,
distress, and depression [3,5,6].
However, in a previous study we demonstrated that only 37 of
76 patients (47%) with incurable cancer had discussions about
limiting treatment or got involved in decisions about limiting
tumor-specific or life-prolonging treatment (eg,
do-not-resuscitate orders) [7]. Oncologists still have difficulties
in discussing treatment limitation with their patients and feel
unsure about when and how to initiate such discussions [8,9].
Against this background, we initiated a monocentric
interventional study aimed at developing an ethical guideline
for end-of-life decision-making, with a goal to increase
oncologists’ awareness of patients’ treatment preferences, to
increase patients’ involvement in decision-making, and to reduce
psychological and moral distress within a caregiver team.
According to many evaluational studies, guidelines can change
clinical practice and may lead to the improvement of physician
performance and patient outcomes [10,11].
While there are many studies on impact and uptake of guidelines
in medical practice, ethical guidelines remain underrepresented
in research and the impact of such guidelines in medical practice
is not well studied. In the following protocol, we explain our
study design for evaluating the impact of ethical guidelines on
the practice of clinical decision-making regarding treatment
limitation. The overall aims of this three-stage interventional
Ethics Policy for Advanced Care Planning and Limiting
Treatment (EPAL) Study are: (1) to develop an ethical guideline
for end-of-life decision making, and (2) to evaluate its impact
on decision-making practice. The guideline will be evaluated
with regard to the following outcomes: better knowledge and
consideration of patients’ treatment wishes, reduction of
decisional conflicts, improvement of documentation
transparency and traceability, and reduction of the psychological
and moral distress of a caregiver team. We also anticipate that
the guideline will enable oncologists to make timelier and
ethically informed treatment limitation decisions.
Methods
Design
This is a pre-post interventional design that analyzes the clinical
practice of decision-making before and after the guideline
implementation. The study consists of three stages: (1) the
preinterventional phase (Time 1 [T1]; status quo), followed by
the (2) intervention phase (development and implementation of
the guideline; T2), and (3) the postinterventional phase (T3).
We use an embedded researcher design with a mixed-method
approach that encompasses both qualitative and quantitative
methods. We assume that using one research method is not
sufficient to answer all of our research questions and that
different methods are required. Embedded researcher design
mixes different data sets at different design phases so that one
data type provides a supportive, supplemental role or is
embedded within other data types [12].
In phase 1 (T1), the current clinical practice of decision-making
and documentation of decisions to limit treatment will be
analyzed from three different perspectives: patients, their
treating oncologists, and nurses. Phase 2 (T2) entails the
development and implementation of a guideline on advanced
care planning and limiting treatment. In phase 3 (T3), the impact
of the guideline on the practice of decision making and
documentation will be analyzed. The project outline is presented
in Table 1. This study protocol has been approved by the Ethics
Committee of the Medical Faculty of the University of Munich.
Study Setting
The study is monocentric and is being carried out at the
Department of Hematology & Medical Oncology at the
University Hospital of Munich, Germany. A monocentric
approach is being used, because the development of a guideline
has proven to be more successful when it is developed within
and for a particular location, taking into account specifics of
the organizational context and of stakeholders’ positions and
professional self-conception of that environment [10].
Phase 1 (T1): Preimplementational Study of Current
Decision-Making Practice of Limiting Tumor-Specific
or Life-Prolonging Treatment
The first phase consists of three studies in which different
methods are applied, with the aim to analyze the current state
of decisions to limit a tumor-specific and life-prolonging
treatment and to understand patients’, oncologists’, and nurses’
needs regarding decisions to limit treatment. The insights from
phase 1 will be used for development of the ethical guideline
and for comparison with the results of phase 3 in order to detect
any impact of the guideline after implementation in the pre-post
comparison.
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Table 1. Project outline.
Sample/participantsData collectionMethodsPhases
1. 500 patients’ records1. Documentation analysis1. Embedded researchPhase 1 (T1): Preinterventional
phase – baseline survey
2. 25 oncologists and nurses2. Semistructured interviews2. Qualitative study
3. 60 patients’ cases (oncologists + nurses)3. Questionnaire3. Quantitative survey
1. Oncologists, nurses, psycho-oncologists, exter-
nal experts for palliative medicine, medical ethi-
cists, medical law, ethics committee
N/Aa1. Group discussions with
experts
Phase 2 (T2): Intervention develop-
ment and implementation of the
ethical guideline
N/AN/A2. Several consensus confer-
ences
1. 500 patients’ records1. Documentation analysis1. Embedded researchPhase 3 (T3): Postinterventional
phase – comparison with the re-
sults of phase 1 and evaluation 2. 60 patient’s cases (oncologists and nurses)2. Questionnaire2. Quantitative survey
aN/A: not applicable.
Phase 1 includes: an observational baseline-survey on
documentation, frequency, and timing of decisions to limit
intensive medical care and tumor-specific therapy; a qualitative
interview study with oncologists and oncology nurses; and a
quantitative survey with patients, nurses, and oncologists.
Observational Baseline-Survey on Frequency and Timing
of Decisions to Limit Intensive Medical Care and
Tumor-Specific Therapy
As a first step of the preimplementational phase, we aim to
examine how often decisions to limit treatment precede patients’
deaths and how early they are determined. This baseline survey
will enable us to investigate whether findings from the
quantitative survey with oncologists, nurses, and patients are
supported by observation and vice versa. The main research
questions of the survey are presented in Textbox 1.
For the observation, we will use a standardized documentation
form. This form will be developed in a multi-step team process
that will encompass literature review and discussions with
experts including oncologists, palliative care physicians, medical
ethicists, and social science experts. The documentation form
will include the following information: patients’ demographic
data and diagnosis, the therapy/ intervention that have decided
to be limited, how decisions to limit treatment are documented,
changes in the scope of decisions to limit treatment, place of
patient’s death, therapy and medication 72 hours before patient’s
death, and whether decisions to limit treatment are followed or
overruled in a patient’s last days.
Methods and Data Collection
We will use a method of an embedded researcher for this part
of the project. The researcher is a member of a hospital team
and participates in patients’ sign-out reports from late to night
shifts. She documents all treatment decisions made by
oncologists. However, her role remains a passive one in order
to avoid any influence on the current situation. If a patient dies,
we will document all relevant decisions that preceded death.
Furthermore, patients’ transfer plans, charts, electronic hospital
acts, and discharge letters will be analyzed.
Participants
All inpatients with advanced hematological/oncological
neoplasia will be included if they are under treatment in at the
Department of Hematology/Medical Oncology at the University
Hospital in Munich.
Data Analysis
Data will be analyzed using Microsoft Excel.
Qualitative Interview Study With Oncologists and Oncology
Nurses
In order to explore in-depth how oncologists and oncology
nurses perceive treatment limitation decisions, a qualitative
approach based on a grounded theory methodology will be used.
Methods and Data Collection
Qualitative individual face-to-face interviews will be conducted
using a semistructured and pilot-tested interview guide. The
interview topics are presented in Textbox 2.
Textbox 1. Research questions.
• How often do decisions to limit treatment precede a patient’s death?
• How often do patients die under chemotherapy or in the intensive care unit?
• How intensely are patients treated shortly before death?
• How well are decisions to limit treatment documented?
• How long before patients' death are decisions to limit treatment made?
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Textbox 2. Main interview topics.
• Treatment limitation situations
• Decision-making process
• Patients’ involvement in decision-making
• Role of patients’ family in decision-making
• Nurses’ role in decisions to limit treatment
• Challenges and conflicts by decisions to limit treatment
• Oncologists’ role in decisions to limit treatment
Procedure and Data Analysis
Purposive and theoretical sampling strategies will be applied.
Participants are purposely sampled to represent different hospital
units, working experience, age, and sex to reflect a wide range
of opinions. The sampling will be continued until the theoretical
saturation will be reached: when no new categories emerge and
the relationships among categories are well-developed [13].
The collected data will be analyzed using the three-stage
approach (open, axial, and selective coding strategies) of
grounded theory methodology. MAXQDA software (VER BI
GmbH, Berlin, Germany) will be used to assist with the coding
and management of transcripts.
Quantitative Survey With Patients, Nurses, and
Oncologists
In order to access and compare the perspective and reports of
parties involved in decisions to limit treatment, we will survey
patients, their respective oncologists, and oncology nurses. The
survey will be complemented by a documentation form
completed by a project researcher on each patient’s case.
Patients’ Survey
Development of the Questionnaires
The study questionnaire will be developed based on a review
of current literature and oncologists’ and nurses’ views and
experiences derived from the interview study. A preliminary
version of the questions will be checked by three experts
(members of the research team) including an experienced
psycho-oncologist, an oncologist with expertise in medical
ethics, and a social scientist. We plan to use both established
instruments as well as self-developed questions.
Established Instruments
The patients’ questionnaire set comprises the questionnaire on:
distress in Cancer Patients [14]; Whooley Depression Scale
[15]; the perceived patients’ quality of life, which will be
measured by a quality of life scale from European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire-C30 [16]; and the trade-off between patients’
preferences for quality and length of life will be assessed with
the Quality and Quantity Questionnaire [17]. We will translate
and validate this questionnaire on a sample of advanced cancer
patients within the scope of this project: the perceived role of
patients’ families in decision-making will be measured with the
scale Family Involvement in Treatment Decisions from the
validated German version of the Cancer Communication
Assessment Tool for Patients and Families [18], and patients’
roles in medical treatment decisions will be assessed with a
German version of Control Preference Scale [19]. Satisfaction
with a physician-patient interaction will be assessed using the
validated questionnaire on the Quality of Physician-Patient
Interaction [20]. We will use self-developed closed-ended
questions with Likert scales to assess: patients’ awareness of
the treatment goal (curative or palliative); patients’ recollection
of discussing the treatment aim; patients’ information needs
regarding disease, prognoses, advance directives, and actual
information received by patients; patients’ communication
preferences regarding treatment limitation; and satisfaction with
decision-making.
Patient Recruitment
The inclusion criteria for patients are presented in Textbox 3.
We will exclude patients with cognitive impairment and/or with
a very poor general state of health. Patients will be recruited
through a project researcher who will identify patients with
decisions to limit treatment. In addition, oncologists will refer
eligible patients when treatment limitation has been/is being
discussed.
Patients will be recruited from five hospital units (n=5 normal
wards) and the recruitment will take place until 60 patients with
decisions to limit treatment are included in the study. All patients
matching the inclusion criteria will be contacted by a project
oncologist who will inform them about study aims and content.
Textbox 3. Inclusion criteria.
• Hospitalized cancer patients (male and female) over 18 years of age
• Diagnosed with advanced hematological/oncological neoplasia
• Decisions to limit treatment being either discussed or determined
• Adequate level of consciousness to complete the questionnaire
• Patients’ agreement through an informed consent document
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Table 2. Topics addressed in the questionnaire.
NursesOncologistsPatientsAssessed topics
——✓Cancer-specific distress
——✓Depression
——✓Information needs regarding disease (eg, prognosis, side effects, life expectation)
——✓Actual received information regarding disease
—✓—Factors that influenced oncologists’ decision of treatment limitation (eg, patients’ age, quality
of life)
✓✓—Estimation of patients’ life expectation
✓✓✓Perceived (estimated) quality of life
✓✓✓Information need for advanced directive/role of the advanced directive
✓✓✓Discussed treatment limitation
✓✓✓Planned or current treatment
—✓—Level of difficulty of treatment limitation decisions
✓✓—Challenges that influenced treatment limitation
✓✓—Consensus relating to treatment limitation decisions
✓✓—Involvement of nurses in decision-making
✓✓✓Perceived aim of the treatment/estimation of patients’ preferences regarding treatment limitation
✓✓✓Discussion of the treatment aim/involvement of patients in decision-making
✓✓✓Preference for quality or length of life
✓✓✓Role in medical decisions
✓✓—Estimation of awareness of patients’ prognosis
✓✓✓Satisfaction with oncologists’ communication/communication with patients
✓✓✓Perceived role of the family, wish for family involvement/involvement of family members
✓✓✓Satisfaction with treatment decisions/consensus with oncologist
✓✓—Perception of optimal time for treatment limitation
✓✓—Moral distress and its reasons
✓✓—Support needs
Oncologists’ and Nurses’ Survey
Development of the Questionnaires
The oncologists’ and nurses’ questionnaire set will be developed
as analogues to the patients’ questionnaire to compare the
answers to the same topics. In addition, we will assess moral
distress in the care team with the Moral Distress Thermometer
[21] and with two self-formulated open-ended questions on
reasons for distress.
Furthermore, we will formulate questions to assess aspects such
as: perceived difficulties by oncologists and nurses with
decisions to limit treatment, oncologists’ and nurses’ satisfaction
with decisions to limit treatment, and involvement of nurses in
decisions to limit treatment. All topics that will be compared
among oncologists, nurses, and patients are presented in Table
2.
Recruitment of Treating Physicians and Nurses at the
Hematology/Oncology Inpatient Unit
For every patient’s case the respective oncologist in charge and
oncology nurse will be surveyed. The respective treating
oncologist of the selected patients will be contacted and asked
to participate in the study.
Data Analysis
Patients’ characteristics will be evaluated using descriptive
statistics. Patient cohorts will be formed based on patients’
preference for length or quality of life, specificity of decease
type (ie, oncological/hematological disease), type of therapy,
and psycho-social variables. To compare the oncologists’,
nurses’, and patients’ views before and after guideline
implementation, the Student t-test for paired data will be
computed. Finally, linear regression analysis will be performed
to identify possible predictors of oncologists’ decisions to limit
treatment and patients’ involvement or noninvolvement in
decision-making. Statistical significance will be assessed at the
level of α=0.05 (two-sided). All statistical analyses will be
conducted using SPSS v.20.
Additional Documentation on Every Patient’s Case
We will develop a special documentation form which will be
completed by a project researcher on every patient’s case, in
addition to the quantitative survey. The aim of this form is to
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gather additional objective information regarding treatment
limitation decisions. The researcher will complete the
documentation form as soon as the patient has completed the
questionnaire (date 1) and will proceed with documentation
seven days later (date 2). If the decision has not been made yet,
the documentation form will be filled approximately three days
later, after date 2 once again (date 3).
Source of Information
The project researcher will screen patients’ medical records to
get necessary patient information. The documentation form will
include information regarding hospital unit, patients’ diagnosis
and performance status (Eastern Cooperative Oncology Group
Performance Status), patients’ distress level at the time of
hospital admission, pain information (numerical rating scale),
type of therapy (eg, tumor-specific therapy [curative/palliative],
anti-infective, radiation, parenteral nutrition, intravenous fluid
substitution, transfusion, long-term medication for secondary
diagnosis), and what additional supportive medication (eg,
analgesics, sedatives) patients receive at the moment of
documentation, as well as the availability of advance directives.
Additionally, the documentation form aims to assess other
information, such as: patients’ wishes regarding decisions to
limit treatment, and if and where it is documented; if decisions
to limit treatment have been made, and if and where they are
documented; and, if a palliative consultation, if
psycho-oncological consultation / support are offered and if
social services are involved. All changes regarding treatment
limitation in the next week will be noted as well.
Phase 2 (T2): Development and Implementation of the
Guideline
The guideline will be developed in four interprofessional
working groups with equal participation of clinic management,
senior and assistant physicians, psycho-oncologists, nursing
management, nurses, and quality managers. In group settings
the participants will discuss different topics related to treatment
limitation, communication, documentation of decisions, and
legal aspects. Each group will formulate statements and
recommendations which will be finally approved by the mandate
holders that are eligible to vote. Finally, the guideline will be
presented to the external experts of palliative medicine, medical
ethics, and medical law for editing and improvement. The
methodology of guideline development will be described in
detail in a separate paper.
The Intervention
After presentation of the guideline at the internal hospital
conference, mandatory training courses will be offered for
oncologists and nurses to become familiar with the application
of the guideline in their daily practice.
Phase 3 (T3): Postinterventional Study of
Decision-Making Practice
After implementation of the guideline, all measurements from
phase 1 (T1), aside from the in-depth qualitative interviews with
oncologists and nurses, will be repeated to assess possible
changes in clinical practice after guideline implementation.
Measure of Compliance to the Guideline
Oncologists’ self-reported compliance to the guideline will be
measured using several additional self-formulated questions on
oncologists’ guideline adherence that will be placed at the end
of the questionnaire in phase 3. These questions will assess if
the guideline will be used by oncologists in every patient’s case
and whether it will be helpful for end-of-life decision making.
Furthermore, a short additional questionnaire is planned to
assess oncologists’ opinions on the applicability and
practicability of the implemented guideline.
Results
Some parts of the project have been completed and published
[17,22]. A qualitative study with 29 oncologists and oncology
nurses revealed that participants had different approaches to
initiation of end-of-life discussions. These approaches were
ethically weighted and a framework for oncologists was
elaborated. This framework favored an anticipatory approach
of preparing patients for forgoing therapy throughout the course
of disease [22]. The preimplementation study of current
decision-making practice (n=567 patients documented)
demonstrated that decisions to limit treatment preceded the
death of many patients with a cancer disease (62/76, 82% of
deceased patients), but usually were made in the last week of
life [17].
Discussion
Overview
This paper describes the study design of an implementation and
evaluation strategy of an ethical guideline for decision-making
related to limiting treatment in advanced cancer patients that is
grounded in empirical data. The pursued goal is to provide an
informed, transparent, and ethically founded approach to
controversial questions associated with treatment limitation,
taking into account a specific environment of a university
hospital.
As far as we are aware, this is the first study of its kind that uses
a mixed-method approach, and involves patients, oncologists,
and nurses to evaluate the impact of an ethical guideline on
clinical practice. According to the literature review on
institutional ethics policies for end-of-life decisions conducted
by Lemiengre et al [23], most studies have focused on the
implementation of do not-resuscitate policies; however, the use
of before-and-after designs is scarce. Some studies deal with
policies on pain, symptom control, and euthanasia [23].
However, there is a lack of pre-post interventional studies on
ethical guideline development.
Study Strengths
Analysis of Different Perspectives
One major strength of this study is the evaluation of
decision-making related to limiting treatment from different
perspectives of oncologists, nurses, and patients, and comparing
them to each other before and after implementation of the
guideline. Additionally, we will analyze oncologists’, nurses’,
and patients’ needs and perceived difficulties in decision-making
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that will allow us to develop a guideline based on the interests
of all parties. Furthermore, we will assess the perspective and
needs of patients with advanced cancer shortly before dying.
This patient group is not easy to include in studies as they are
very weak and need a sensitive approach when they are assessed
on end-of-life topics.
Mixed-Method Approach
An important strength of this study is the application of different
methods and the collection of multiple sources of data
(interviews, observations, and surveys) and perspectives of
different parties (patients, oncologists, and nurses) to study the
same topic. The triangulation of data contributes to the
credibility of the results and will make the findings more
grounded, thereby offsetting the weaknesses of both quantitative
and qualitative research [12].
Multidisciplinary Team
For all phases of the project we will engage with a
multidisciplinary team that includes experienced experts from
psycho-oncology, sociology, clinical oncology, nursery,
palliative medicine, and medical ethics. Decision-making at the
end of life is a complex process that faces challenges of
psychological, medical, and ethical natures. Different
professional backgrounds and skills could provide a better
framework for analysis and understanding of this process.
Study Limitations
One of the considerable limitations is a well-documented
challenge that is associated with the pre-post interventional
design studies. Pre-post studies assume that any difference in
measurement in “prestudy” compared with “poststudy” is due
to the intervention; however, they do not account for other
elements that are also changing at the same time that the
intervention is taking place. It is difficult to determine if a
certain intervention has indeed produced observed improvement.
A further limitation is that we have to use different patients’
samples in pretests and posttests. The development and
implementation of the guideline will take some time and many
patients will not be available to participate in the posttest
measurements. Furthermore, we must consider that by partaking
in in-depth qualitative interviews and a very extensive
questionnaire, the awareness of ethical issues among oncologists
and nurses could be considerably raised. Consequently, it is
difficult to distinguish the effects of the study itself on the
clinical practice of decision-making from the effects caused by
the guideline implementation. However, we should note that
there is a high rate of fluctuation in a university hospital and
this argument might not apply.
Additionally, the observed improvement could be due to the
so-called Hawthorne effect (or observer effect) when participants
change or adapt their behavior due to the awareness of
observation and assessment [24]. This effect is not easy to
quantify. However, literature suggests that triangulation of data
using a variety of methods from different sources can contribute
to reducing or even overcoming the mentioned effect [25,26].
A further limitation is related to certain particularities of a large
university hospital setting. A characteristic of a university
hospital environment is that junior staff at the wards rotate every
3-6 months. Consequently, some junior oncologists that
participate in the preintervention phase may not have been
present at the guideline implementation phase as well as at the
postevaluation phase.
Conclusion
The results of this study aim at improving the development and
implementation of ethical guidelines into clinical practice. We
expect that our intervention will contribute to improvements in
the decision-making processes on treatment limitation in patients
with advanced cancer, increase the awareness for patient
treatment preferences and their involvement in decision-making,
and reduce psychological and moral distress within the caregiver
team. Another expected outcome of the intervention is
improvements in documentation transparency and traceability.
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